A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study (Q36455403)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

14 August 2017

A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study (English)

1 reference

Europe PubMed Central

14 August 2017

0 references

1 reference

based on heuristic

inferred from title

object named as

Frank M Balis

7

0 references

Roger E McLendon

4

object named as

Roger E McLendon

1 reference

Europe PubMed Central

14 August 2017

author name string

Katherine E Warren

1

1 reference

Europe PubMed Central

14 August 2017

Sri Gururangan

2

1 reference

Europe PubMed Central

14 August 2017

J Russell Geyer

3

1 reference

Europe PubMed Central

14 August 2017

Tina Young Poussaint

5

1 reference

Europe PubMed Central

14 August 2017

Dana Wallace

6

1 reference

Europe PubMed Central

14 August 2017

Stacey L Berg

8

1 reference

Europe PubMed Central

14 August 2017

Roger J Packer

9

1 reference

Europe PubMed Central

14 August 2017

Stewart Goldman

10

1 reference

Europe PubMed Central

14 August 2017

Jane E Minturn

11

1 reference

Europe PubMed Central

14 August 2017

Ian F Pollack

12

1 reference

Europe PubMed Central

14 August 2017

James M Boyett

13

1 reference

Europe PubMed Central

14 August 2017

Larry E Kun

14

1 reference

Europe PubMed Central

14 August 2017

publication date

4 October 2011

1 reference

Europe PubMed Central

14 August 2017

Journal of Neuro-Oncology

1 reference

Europe PubMed Central

14 August 2017

106

1 reference

Europe PubMed Central

14 August 2017

3

1 reference

Europe PubMed Central

14 August 2017

643-649

1 reference

Europe PubMed Central

14 August 2017

https://scigraph.springernature.com/pub.10.1007/s11060-011-0709-z

0 references

Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

30 September 2017

Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

30 September 2017

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

30 September 2017

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

30 September 2017

Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

30 September 2017

Chemoradiotherapy in malignant glioma: standard of care and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

30 September 2017

Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

30 September 2017

MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

30 September 2017

ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

30 September 2017

Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

30 September 2017

Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

30 September 2017

Clinical relevance of MGMT in the treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

30 September 2017

Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

30 September 2017

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

30 September 2017

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

30 September 2017

Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

30 September 2017

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

30 September 2017

O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

30 September 2017

NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

30 September 2017

DNA damage tolerance, mismatch repair and genome instability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

30 September 2017

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

30 September 2017

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

30 September 2017

Activity of temozolomide in the treatment of central nervous system tumor xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

30 September 2017

O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

28 June 2018

Temozolomide as first-line agent in treating high-grade gliomas: phase II study.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0709-Z

21 January 2018

Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0709-Z

21 January 2018

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0709-Z

21 January 2018

Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0709-Z

21 January 2018

Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0709-Z

21 January 2018

Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0709-Z

21 January 2018

Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0709-Z

21 January 2018

Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0709-Z

21 January 2018

Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0709-Z

21 January 2018

Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0709-Z

21 January 2018

Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0709-Z

21 January 2018

O6-benzylguanine-mediated enhancement of chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

21 September 2018

Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3518022

21 September 2018

Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and time course of peripheral blood mononuclear cell O6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate

1 reference

https://pubmed.ncbi.nlm.nih.gov/21968943

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11060-011-0709-Z

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36455403&oldid=1981718466"